Scope Fluidics gets EIB loan for infection diagnostics
The European Investment Bank has lend up to €10m to Polish microbial diagnostics specialist Scope Fluidics AS.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2000 entries already.
Entries by Thomas Gabrielczyk
COVID-19: Roche AG launches antigen rapid test
Roche has announced to launch a SARS-CoV-2 point-of-care antigen test this month co-developed with SD Biosensor Inc. (South Korea).
Unilever to replace fossil carbon in cleaning products
Unilever has announced to invest €1bn globally to eliminate fossil fuels as a source of carbon in its cleaning products by 2030.
Interview: Neciah Dorh, CEO, FluoretiQ
15min to detect bacterial infections – that’s what British diagnostics company FluoretiQ Ltd is offering in the fight against antimicrobial resistance. A short interview with CEO Neciah Dorh.
Stakeholders push for further pull incentives
With around 450 attendees, the five-day digital conference particularly focused on market conditions and financing. SMEs and global partners urged for more pull incentives.
Bioversys bags €17.7m financing
Swiss BioVersys AG has secured a CHF19m Series B financing to push clinincal development of two antiinfectives against drug-resistant pathogens.
Sotio licences Unum Therapeutics’ CAR-T cell portfolio
PPF-owned company SOTIO has acquired the rights to use the BOXR CAR-T platform and products from Cambridge-based Unum Therapeutics.
Polyphor partners with Fosun Pharma
Polyphor AG has licenced its metastatic cancer drug balixafortide to Fosun Pharma Co Ltd to market the drug exclusively in China.
Engitix Ltd. lands US$500m deal with Takeda in fibrosis
British fibrosis therapeutics start-up Engitix Ltd has entered a collaboration agreement with Takeda to develop anti-fibrotic therapies in liver diseases.
Moderna set to deliver COVID-19 jab to the EU
US experiemental mRNA vaccine maker Moderna Inc is in advanced talks with the European Commission to supply 80 million doses mRNA-1273, its candidate vs SARS-CoV-2